OR WAIT 15 SECS
Thermo Fisher Scientific and Cedars-Sinai have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive LC–MS-based workflows for clinical research applications.
Thermo Fisher Scientific (Waltham, Massachusetts, USA) and Cedars-Sinai (Los Angeles, California, USA) have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive liquid chromatography–mass spectrometry (LC–MS)-based workflows for clinical research applications.
“Thermo Fisher shares our vision for helping clinical research teams set new standards for excellence and innovation in patient care through precision medicine. The goal is to develop advanced
LC–MSâbased workflows for the untargeted screening and targeted quantitation of protein-based biomarkers for critical disease states, which hold the potential to benefit not only our own patients but also the wider clinical community,” said Jennifer Van Eyk, Ph.D., Principal Investigator for Research and Director of the Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences at Cedars-Sinai.
For more information, please visit www.thermofisher.com/BeSure